AFX logo

Carl Zeiss Meditec AG Stock Price

XTRA:AFX Community·€2.4b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 59 Fair Values set on narratives written by author

AFX Share Price Performance

€27.28
-32.22 (-54.15%)
€39.27
Fair Value
€27.28
-32.22 (-54.15%)
30.5% undervalued intrinsic discount
€39.27
Fair Value
Price €27.28
AnalystConsensusTarget €39.27
AnalystLowTarget €22.40
AnalystHighTarget €64.22

AFX Community Narratives

AnalystConsensusTarget·
Fair Value €39.27 30.5% undervalued intrinsic discount

VISUMAX 800 Approval In China Will Strengthen Future Market Position

1users have liked this narrative
0users have commented on this narrative
32users have followed this narrative
AnalystLowTarget·
Fair Value €22.4 21.8% overvalued intrinsic discount

Regulatory Uncertainty And Trade Tensions Will Depress Margins

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AnalystHighTarget·
Fair Value €64.22 57.5% undervalued intrinsic discount

Digital And AI Advances Will Expand Global Eye Care Markets

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
€22.4
21.8% overvalued intrinsic discount
Revenue
2.54% p.a.
Profit Margin
7.77%
Future PE
9.74x
Price in 2029
€26.77
€39.27
30.5% undervalued intrinsic discount
Revenue
3.71% p.a.
Profit Margin
8.5%
Future PE
19.58x
Price in 2029
€46.63
€64.22
57.5% undervalued intrinsic discount
Revenue
6.48% p.a.
Profit Margin
11.97%
Future PE
20.82x
Price in 2029
€75.65

Trending Discussion

Updated Narratives

AFX logo

AFX: Lower Guidance And China Tender Pressures Will Drive Further Multiple Compression

Fair Value: €22.4 21.8% overvalued intrinsic discount
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
AFX logo

AFX: Long Term Partnerships Will Support Future Upside After Recent Rating Cuts

Fair Value: €39.27 30.5% undervalued intrinsic discount
32 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
AFX logo

AFX: Long-Term Alliances Will Underpin Future Upside Potential

Fair Value: €64.22 57.5% undervalued intrinsic discount
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Undervalued with excellent balance sheet and pays a dividend.

1 Risk
3 Rewards

Carl Zeiss Meditec AG Key Details

€2.2b

Revenue

€1.1b

Cost of Revenue

€1.2b

Gross Profit

€1.0b

Other Expenses

€120.6m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
May 12, 2026
1.38
52.19%
5.47%
25.1%
View Full Analysis

About AFX

Founded
1846
Employees
5784
CEO
Andreas Pecher
WebsiteView website
www.zeiss.com/meditec-ag/de/investor-relations.html?vaURL=www.zeiss.de/meditec-ag/ir

Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis and treatment of chronic eye diseases, including slit lamps, refractometers, and tonometers; optical coherence tomography and fundus cameras for retina examination; functional glaucoma diagnostic devices (perimeters); surgical ophthalmology products comprising surgical microscopes, biometers, and phacoemulsification and vitrectomy equipment; intraocular lenses for cataract surgery; and systems and consumables for laser eye surgery that include the VISUMAX femtosecond laser, which enables minimally invasive correction of vision defects using lenticular extraction, as well as digital products for the storage, analysis, and sharing of clinical data. The Microsurgery segment provides products and solutions for minimally invasive surgical treatments, including surgical visualization, interoperative radiotherapy, interoperative pathology, special surgical instruments, and digital solutions, as well as the ZEISS Tumor Workflow, a cross-product workflow solution. It serves physicians in various fields and hospitals. The company was founded in 1846 and is headquartered in Jena, Germany. Carl Zeiss Meditec AG operates as a subsidiary of ZEISS Group.

Recent AFX News & Updates

Recent updates

No updates